Ipsen inks $137M cancer drug deal; Agios shares rocket up as presentation looms;

@FierceBiotech: Michigan investigators zero in on a new approach to a Notch cancer drug. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Following pioneering approval, Versant bankrolls next-gen oncolytics player Turnstone. Article | Follow @JohnCFierce

@DamianFierce: $MGNX gets the last laugh by misspelling "Servier" in its breakup announcement. Release | Follow @DamianFierce

> France's Ipsen has struck a deal to in-license development and commercialization rights to Montreal-based Telesta Therapeutics' MCNA for non-muscle invasive bladder cancer. Ipsen gains all rights outside of the United States, where Telesta is setting up commercial ops, Canada, South Africa, South Korea, Japan and Mexico. Telesta earns a $10 million upfront, up to $127 million in milestones and double-digit royalties. Release

> Shares of Agios ($AGIO) shot up 24% on Tuesday after the biotech announced that it plans to release new data on AG-120 in about a week. Release

Medical Device News

@FierceMedDev: NEA backs cancer genome Dx startup Personal Genome in $21M+ Series A. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: J&J device heads say the new med tech innovation model calls for more external partnerships. Story | Follow @VarunSaxena2

@EmilyWFierce: "Leadership is about creating futures that are not a direct path." - @broadinstitute's COO Samantha Singer. More/Feature | Follow @EmilyWFierce

> J&J's Ethicon partners with Fogarty Institute to back next-gen device innovation. Report

> Medtronic touts studies of its devices to monitor patients following sedation. Story

> Cleveland Clinic, Candescent Health partner to create cloud-based radiology network. More

Pharma News

@FiercePharma: Amgen's T-Vec wins FDA nod, EU committee recommendation. FierceVaccines story | Follow @FiercePharma

@EricPFierce: GSK says it 'takes seriously' issues at China plant that led UK regulators to pull GMP cert. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Pfizer blows past sales forecasts, thanks to overachievers Prevnar, Ibrance. Story | Follow @CarlyHFierce

> Express Scripts: AbbVie hep C meds still available for the right patients. News

> Valeant draws more fire for tapping insiders to investigate fraud allegations. More

> Gilead faces Q3 slowdown for hep C superstars. Story

Biotech Research News

> JAK inhibitors demonstrate fresh promise in restoring hair growth. Report

> Restoring testosterone production may be safer than replacement treatments. Item

> Howard Hughes researcher IDs a new target for autoimmune disease. More

> Michigan investigators zero in on a new approach to a Notch cancer drug. Story

> Drug-device combo from Wyss takes a new approach on treating stroke. Article

Pharma Marketing News

> Shire nabs much-needed PhIII boost for dry-eye prospect lifitegrast. Item

> Merck says it won't need AbbVie-sized discounts to win in hep C. Article

> With competition heating up, Pfizer may drop psoriasis effort on Xeljanz. Report

> Merck's Keytruda has a shot at a bigger share of NSCLC sales. Story

> No exodus from DPP-4s on Jardiance CV data, but SGLT2 scripts are shifting: Merck. More

Vaccines News

> GSK's malaria vaccine hits roadblock as WHO recommends pilot projects. News

> Pfizer continues vaccines hot streak with 43% Q3 growth. Report

> Amgen's T-Vec wins FDA nod, EU committee recommendation. Story

> GSK reports PhIII success for shingles jab, will file for approval in late 2016. Article

> SciVac Therapeutics agrees to acquire VBI Vaccines. Item

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.